Ono Pharmaceutical Co., Ltd.

Tomoya Tezuka

Shiro Shibayama

Mark Throsby

Pieter Fokko Van Loo

Rinse Klooster

Cornelis Adriaan De Kruif

Takuya Shimbo

Robertus Cornelis Roovers

An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.

Bispecific antibody

A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.

Growing community of inventors

Ibaraki, Japan

Tomoya Tezuka